Pretreatment upper-GI cancer organoid models for tailoring neoadjuvant treatment regimens

Pretreatment upper-GI cancer organoid models for tailoring neoadjuvant treatment regimens - Pretreatment upper-GI cancer organoids

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49596

Enrollment

320

Registered

2019-05-21

Start date

2019-11-08

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer gastric cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with histologically proven adeno- or squamous cell carcinoma of the stomach or esophagus who are eligible for treatment with curative intent. Signed informed consent.

Exclusion criteria

Exclusion criteria: - Inability to undergo gastroduodenoscopy - Severe coagulopathy with uacceptable risk of bleeding due to biopsy procurement

Design outcomes

Primary

Measure	Time frame
Correlation between the in vitro respons of the organoid and the in vivo respons in the patient to the established neoadjuvant treatment regimens	—

Secondary

Measure	Time frame
Identification of (epi)genetic differences on the DNA, RNA or protein level between the organoids of patients with response and non-response, as well as organoids from the same patient derived before and after treatment.	—

Countries

Netherlands

Outcome results